The FDA approved an at-home injectable starting dose of Leqembi, Biogen announced plans for a Phase 3 trial of the tau-silencing therapy diranersen, and a Phase 2 trial found that a THC and CBD formulation rapidly reduced agitation in people with advanced dementia.